Moderna Inc. (NASDAQ:MRNA) is set to clash with Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a pivotal London patent trial concerning the development of COVID-19 vaccines. The High Court is ...

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for children aged 6 months to 5 years old. Both vaccines are mRNA based, made ...

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). These two vaccine makers ...

LONDON, April 23 (Reuters) - Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global ...

While the overall theme of Moderna’s quarterly earnings presentation on Thursday was that the company is moving away from its coronavirus vaccine and onto a host of other mRNA products in development, ...

A few years ago, both Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine -- and Pfizer ...

Despite a U.S. factory mixup, more Johnson & Johnson doses are becoming available in the U.S., marking the only single-shot vaccine option. So how effective is it and how does it compare to the Pfizer ...

Pfizer has a deep lineup and pipeline, generates consistent results, and pays dividends. Moderna is on the verge of key approvals and has exciting pipeline candidates in the works. One of these ...